Subscribe to Newsletter

Content by Mark Hillen:

 Subspecialties Retina

Releasing the Gene Genie

| Mark Hillen

The gene therapy era in ophthalmology edges nearer and is making RP… treatable.
Business & Profession Other

Access All Areas

| Mark Hillen

Why, in terms of congresses, bigger isn't always better.
Subspecialties Imaging & Diagnostics

Consumer Reports

| Mark Hillen

Four OCT-A devices go head-to-head. Was there a winner?
Subspecialties Imaging & Diagnostics

Traveling Without Moving

| Mark Hillen

How "making light dance" can eliminate speckles from OCT scans.
Business & Profession Other

Real World Evidence – and Rat Poison

| Mark Hillen

Why practical hurdles help inferior drugs perform better in clinical trials than in real life.
Subspecialties Retina

CLARITY Achieved

| Mark Hillen

Can an anti-VEGF agent outdo PRP for the treatment of PDR?
Business & Profession Refractive

Business in Brief

| Mark Hillen

Collaborations, acquisitions and a potential case of misleading information…
Business & Profession Other

The Big News Is Big Data

| Mark Hillen

Might the next Nobel Prize in Physiology or Medicine go to a coder, rather than a researcher or doctor?
Subspecialties Glaucoma

When Multiple Punctures Don’t Deflate

| Mark Hillen

Repeated bevacizumab injections increase the risk of glaucoma surgery.
Subspecialties Retina

Retinal Prostheses: The Next Generation

| Mark Hillen

Two approaches that could result in a better retinal implant.
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

April Issue of The Ophthalmologist
Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: